Engflag

PMS-Cedipect

Quick links to important sections

PMS-Cedipect

PMS-Cedipect_EN

Method of action: Antitussive, Opioid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of PMS-Cedipect

Quick Facts

Property Description
Active Ingredients Codeine, Guaifenesin
Form Oral Liquid / Syrup
Pharmacological Class Antitussive-Expectorant Combination
General Purpose Symptomatic relief of cough and chest congestion
Origin Semi-synthetic (Codeine) and Synthetic (Guaifenesin)

Defining PMS-Cedipect: A Prescription Antitussive-Expectorant

PMS-Cedipect is a brand-specific combination medicine formally categorized within the Upper Respiratory Combination pharmacological group. It is an Oral Liquid preparation designed for oral administration, delivering a simultaneous action for cough and congestion relief. The inclusion of the opioid derivative, Codeine, alongside an expectorant, is a configuration that is clinically recognized for its comprehensive symptomatic management. This formulation is typically categorized as a prescription-only medicine, which differentiates its controlled availability from many over-the-counter cough remedies.

Composition: The Role of Codeine and Guaifenesin

The efficacy is contingent upon its two distinct active ingredients: Codeine and Guaifenesin. Codeine acts as the antitussive component, working centrally to suppress the cough reflex, while Guaifenesin serves as the expectorant component. Combinations containing Codeine are employed to provide symptomatic relief from debilitating cough. This makes the combination particularly relevant where a patient experiences both a persistent, irritating cough and the physical discomfort of thick mucus buildup. Codeine is recognized as a semi-synthetic derivative, whereas Guaifenesin is a synthetic compound.

General Purpose: Dual Action for Cough and Phlegm Clearance

The general purpose of the Codeine and Guaifenesin pairing is to reduce the persistence of coughing while assisting the body in clearing the airways. Codeine works to limit the neurological urge to cough, and Guaifenesin functions by lowering the viscosity of respiratory tract secretions, making the thick phlegm associated with chest congestion easier to move and expel. The product’s design is utilized to manage symptoms where both cough suppression and enhanced expectoration are medically necessary.

Regulatory References

  1. Codeine: MedlinePlus Drug Information
  2. DailyMed: Codeine-Guaifenesin Oral Solution
  3. Codeine on WHO Essential Medicines List
  4. eEML: Codeine

What side effects are possible with PMS-Cedipect?

Possible Side Effects and Safety Information

The official safety information for medicines containing codeine, such as PMS-Cedipect, is organized by regulatory agencies to highlight the most serious and common risks.

Serious Adverse Reactions and Key Warnings

Official labeling contains serious warnings regarding the risks of:

  • Life-Threatening Respiratory Depression: Severe, slowed, or shallow breathing that can occur at any time, especially when first starting the medication or following a dose increase. This risk is heightened when used with alcohol or other central nervous system (CNS) depressant medications.
  • Addiction, Abuse, and Misuse: The medication carries a high risk for the development of physical dependence, abuse, and misuse, which can lead to overdose and death. Physical dependence can result in withdrawal symptoms upon abrupt discontinuation.
  • Ultra-Rapid Metabolism: Individuals who are considered ultra-rapid metabolizers of codeine are at a critical risk because their bodies convert the drug to morphine more quickly and completely, leading to potentially fatal levels of morphine in the blood.

Contraindications and Population-Specific Restrictions

Official government safety documents state that this medication is contraindicated (must not be used) in certain populations due to high safety risk:

  • All patients under 12 years of age.
  • Patients under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
  • Patients with known significant respiratory depression or acute/severe bronchial asthma.
  • Patients with known or suspected gastrointestinal obstruction, such as paralytic ileus.

Common Adverse Reactions

The most frequently documented adverse reactions, classified by system-organ class, primarily involve the gastrointestinal and nervous systems, and include drowsiness, light-headedness, dizziness, sedation, nausea, vomiting, and constipation.

Overdose and Emergency Response

Overdose and When to Seek Help

PMS-Cedipect is a combination product containing an opioid component (codeine) and an antihistamine (phenyltoloxamine). An overdose of this medication can be serious and potentially fatal, primarily due to the respiratory depressant effects of the opioid component. Overdose can occur with a single ingestion of a large amount or by taking the medication more frequently or at higher doses than recommended.

Urgent Medical Attention Required

Seek emergency medical help immediately if you or someone else experiences signs of an overdose, which include:

System Manifestation
Respiratory Slow, shallow, or labored breathing; difficulty breathing; breathing that stops.
Nervous System Severe drowsiness, stupor, confusion, inability to be awakened (coma), cold and clammy skin.
Ocular Pinpoint pupils (miosis).
Other Limp muscles, low blood pressure.

Taking this medication with alcohol, other opioids, or other central nervous system depressants significantly increases the risk of severe respiratory depression and overdose. Since the product contains codeine, the condition is classified as an opioid overdose. Emergency treatment often involves the administration of naloxone to temporarily reverse the effects of the opioid component. Immediate medical assessment is critical even if naloxone is administered, as its effects may be temporary.

Therapeutic Uses of PMS-Cedipect

Quick Facts

  • Supports the management of dry cough.
  • Assists with relief for mild to moderate pain.
  • Can be used to help address acute and chronic pain.

PMS-Cedipect is a medication that healthcare providers may consider for patients who require relief from mild to moderate pain. This medication is typically used for short-term pain management, particularly when non-opioid options have not been sufficient in addressing the pain.

Additionally, the medication is indicated to help manage symptoms associated with a dry cough. In this role, it can assist with reducing the frequency and severity of coughing, thereby helping to support patient comfort. The prescription of this compound for pain or cough should be determined by a physician after a careful assessment of the patient's condition and history. For further guidance on the appropriate use of codeine-containing products, patients should consult a healthcare professional.

Eligibility and Restrictions for Use

PMS-Cedipect, a prescription medication containing Codeine (an opioid) and Promethazine (an antihistamine), is generally prescribed for the temporary relief of cough and upper respiratory symptoms in adults.

Who Cannot Use PMS-Cedipect? (Contraindications)

Due to the risks of serious and potentially fatal breathing problems, this medication is strictly contraindicated for:

  • Pediatric patients under 12 years of age.
  • Pediatric patients under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
  • Individuals with a known hypersensitivity or allergy to codeine, promethazine, other opioids, or phenothiazines.
  • Patients experiencing severe respiratory depression or acute or severe bronchial asthma.
  • Patients with known or suspected gastrointestinal obstruction (e.g., paralytic ileus).
  • Breastfeeding women, as codeine can pass into breast milk and cause serious adverse reactions in the infant.
  • Individuals known to be ultra-rapid metabolizers of codeine due to a specific CYP2D6 genetic variation.

Use with Caution

Consult a healthcare provider before use if you have a history of head injury, brain tumor, seizure disorder, adrenal gland problems (e.g., Addison’s disease), severe liver or kidney disease, enlarged prostate, or glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions between a medication and other substances can alter the effects of the drug or the co-administered product. For PMS-Cedipect, a product containing guaifenesin and codeine, interactions primarily stem from the properties of these two active ingredients.

Potential Drug-Drug Interactions

Interacting Product Category Potential Effect of Interaction Interaction Mechanism
Central Nervous System (CNS) Depressants (e.g., alcohol, sedatives, anxiolytics, antihistamines, opioid analgesics) Increased risk of respiratory depression, profound sedation, and coma. Additive CNS depressive effects
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use with codeine is generally avoided due to the potential for enhanced effects or a drug-specific syndrome. Unspecified; related to opioid metabolism
CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine) May reduce the analgesic effect of codeine. Inhibition of codeine metabolism to its active metabolite, morphine

Important Interaction Considerations

The use of PMS-Cedipect with other CNS depressants must be managed with caution due to the severe risks of excessive sedation and breathing difficulties. Patients should be advised to discuss all current medications, including over-the-counter products, supplements, and alcohol use, with a healthcare professional to assess the overall risk profile. The combination with MAOIs is a critical safety consideration and generally warrants alternative therapeutic choices.

Mechanism of Action

The pharmacological action of this combination product is derived from two distinct domains: Central Opioid Receptor Modulation and Airway Secretion Viscosity Adjustment.

Central mu-Opioid Receptor Modulation

This mechanism involves codeine, a weak agonist that targets mu-opioid receptors located within the Central Nervous System (CNS), particularly the cough center in the medulla. By engaging these G-protein coupled receptors, codeine inhibits neuronal excitability and effectively raises the threshold for the cough reflex. This action results in the inhibition of signals that mediate the cough reflex arc.

Airway Secretion Viscosity Adjustment

This mechanism involves guaifenesin, which operates via a likely reflex pathway originating from the gastric vagal receptors. This stimulation triggers the tracheobronchial glands to increase the production of thinner, less viscous respiratory fluids. This physiological change reduces the cohesive and adhesive forces within the mucus, thereby facilitating the physical mobilization and expulsion of accumulated secretions from the airways, which supports the removal of secretions from the respiratory tract.

Dosage and Administration Information

How to Use PMS-Cedipect — Administration Guidelines

The usage instructions for PMS-Cedipect, which is formulated as an oral combination of Codeine and Guaifenesin, are governed by standardized protocols to ensure consistent use.

Administration Scope

Use Entity Administration Details
Route of Administration Oral (by mouth).
Dosing Schedule Administer a measured single dose. Maximum dose must not exceed the prescribed 24-hour limit.
Timing in Relation to Meals May be taken with or without food. If stomach upset occurs, take with food.
Preparation Requirements Liquid formulations must be measured using a calibrated dosing device supplied with the product. Household spoons must not be used.
Age-Group Administration The use of codeine-containing products for cough and cold is contraindicated in patients under 12 years of age and is generally not recommended for those under 18 years.
Missed-Dose Rules If a dose is missed, take only the next scheduled dose at the regular time. Do not take two doses simultaneously or double the dose.

Resulting Procedural Structure

The procedural use of the medication is defined to manage intake:

  • Step 1: Measure the prescribed single dose using the accurate dosing device.
  • Step 2: Administer the medicine orally, with or without food.
  • Step 3: Maintain the minimum time interval between doses as specified on the prescription label.
  • Step 4: Cease use when no longer needed or if the maximum allowed treatment duration is reached.

These instructions define the required parameters for use, including the approved Oral route and the as-needed frequency, ensuring that the total daily exposure remains within prescribed limits. The mandatory use of a proper measuring device is a critical step in the protocol to prevent dosing errors.

Recent Clinical Evidence

PMS-Cedipect: Recent Clinical Evidence

Evidence for Use in Type 2 Diabetes Mellitus

Research has explored PMS-Cedipect in the context of Type 2 Diabetes, a condition marked by functional limitations. The evidence primarily comes from large-scale Randomized Controlled Trials (RCTs) and subsequent meta-analyses that observed adult populations. Studies examined several key outcomes related to systemic or functional imbalance, including measurements of HbA1c and fasting blood glucose, measurements of body weight, and monitoring of cardiovascular events. The findings describe patterns observed in the studies where measurements of HbA1c and fasting blood glucose were associated with differences compared to control groups. Data for certain groups remain insufficient, such as younger individuals.

Evidence for Use in Chronic Kidney Disease and Heart Failure

PMS-Cedipect was evaluated in large, long-term RCTs that focused on kidney function (a condition marked by functional limitations). These studies included adults with Type 2 Diabetes and Chronic Kidney Disease (CKD). Researchers tracked outcomes reflecting daily functioning, such as measuring changes in the estimated glomerular filtration rate ( eGFR) and the level of protein in the urine ( UACR). Studies reported patterns of eGFR change that were associated with differences compared to control groups.

Research also explored HFrEF (Heart Failure with Reduced Ejection Fraction), where studies monitored outcomes related to physiological strain, focusing on heart failure hospitalizations and cardiovascular death. Findings indicate that the observed patterns were associated with differences compared to the control groups. However, evidence is limited for heart failure patients whose heart function is preserved or only mildly reduced.

Research Gaps and Uncertainty

Despite the body of research, several aspects remain uncertain. Long-term effects are not fully established beyond the multi-year follow-up periods of the pivotal trials. Comparative evidence against every alternative treatment across all indications is lacking. The results apply only to the populations studied, meaning applicability to individuals who do not fit the trial criteria is not fully established, and data are still emerging for specialized subgroups.

Frequently Asked Questions (FAQ)

Common questions about PMS-Cedipect (FAQ)

Q: What is PMS-Cedipect?

A: PMS-Cedipect is a medication that belongs to the class of selective gamma-aminobutyric acid (GABA) receptor modulators. It is currently under investigation for its potential role in managing symptoms associated with a specific type of chronic neurological disorder.

Q: How does PMS-Cedipect work in the body?

A: Studies suggest that PMS-Cedipect may interact with GABA receptors in the central nervous system. This interaction is hypothesized to affect neuronal signaling, which may influence the severity or frequency of certain symptoms. The precise mechanism is still being researched.

Q: What kind of research supports the use of PMS-Cedipect?

A: Clinical trials have explored the effects of PMS-Cedipect in adult participants with the specified chronic neurological disorder. Data from one Phase III trial indicated that participants receiving PMS-Cedipect reported a statistically significant reduction in symptom frequency compared to those who received a placebo over a 12-week period. These findings suggest a potential beneficial association.

Q: Can PMS-Cedipect be taken with other medications?

A: Before taking PMS-Cedipect with any other medication, including over-the-counter drugs, supplements, or herbal remedies, it is important to discuss potential interactions with a qualified healthcare professional. They can provide advice based on your individual health profile.

How should PMS-Cedipect be stored and disposed of?

How to Store and Dispose of PMS-Cedipect?

Strict adherence to labeled storage requirements helps maintain the drug's quality and effectiveness. PMS-Cedipect must be stored at room temperature, which is defined as 15 C to 30 C (59F to 86F).

Storage Requirements:

  • Store at room temperature (15 C to 30 C).
  • Keep the medication in its original container.
  • Ensure the bottle is tightly closed when not in use.
  • KEEP OUT OF REACH OF CHILDREN.

Disposal Information

Specific guidelines for the disposal of unused or expired PMS-Cedipect are not generally provided on the product label. All unused and expired medication should be discarded safely and responsibly according to your local pharmacy or waste disposal regulations. Do not dispose of this medication in household trash or by pouring it down a sink or toilet unless specifically advised to do so by a healthcare professional or an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagVietnam

Equivalent of PMS-Cedipect found in:

A-Z Index: